[Hypertension and heart failure. Are there approaches for differential therapy?]

Area of Science:

• Cardiology
• Pathophysiology
• Pharmacology

Context:

• Heart failure development involves interstitial changes and myocardial contractility issues.
• Neuroendocrine activation exacerbates structural changes, forming a detrimental cycle.
• Understanding these mechanisms is crucial for effective heart failure management.

Purpose:

• To elucidate the pathophysiological mechanisms driving heart failure progression.
• To highlight the importance of targeted interventions in managing cardiac insufficiency.
• To emphasize the role of specific drug classes in early-stage treatment.

Summary:

• Heart failure arises from various pathophysiological processes, including interstitial alterations and impaired myocardial contractility.
• These factors trigger neuroendocrine activation, leading to structural cardiac remodeling and a self-perpetuating cycle.
• Interfering with this cycle through individualized treatment is key to preventing manifest cardiac insufficiency.

Impact:

• Early intervention can prevent the progression to severe cardiac insufficiency.
• Targeted therapies, such as ACE inhibitors and AT1-antagonists, are vital for incipient cardiac insufficiency.
• This approach aims to break the vicious cycle and improve patient outcomes.